[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-polydipsia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-polydipsia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636759","copeptin-measurement-after-mannitol-and-hypertonic-saline-for-the-diagnosis-of-polyuria-polydipsia-syndrome-100636759",false,"NCT07569861","Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome","COMPASS","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hypotonic polyuria\u002Fpolydipsia syndrome defined as polyuria \\>40ml\u002Fkg body weight\u002F24h and polydipsia \\>3l\u002F24h; and urine osmolality \\\u003C800mOsm\u002FL or known AVP-D based on accepted criteria\n\nExclusion Criteria:\n\n1. Polyuria\u002Fpolydipsia secondary to diabetes mellitus, hypercalcemia, or hypokalemia\n2. Diagnosis of AVP-R (Copeptin \\> 21.4 pmol\u002FL)\n3. Evidence of acute illness\n4. Epilepsy requiring treatment\n5. Uncontrolled arterial hypertension (blood pressure \\>160\u002F100mmHg at baseline\n6. eGFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2\n7. Cardiac failure (NYHA III-IV)\n8. Diagnosis of liver cirrhosis, Child-Pugh Class C\n9. Uncorrected adrenal or thyroidal deficiency\n10. Pregnancy or breastfeeding\n11. Current or unresolved urinary obstruction\n12. Enrollment in a clinical trial within the last 30 days\n13. Patients refusing or unable to give written informed consent\n14. Inability to follow study procedures","ALL","18 Years",{"count":19,"type":20},144,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to evaluate whether a new test using mannitol infusion can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current standard test (hypertonic saline infusion) and to compare which test patients prefer. The goal is to identify a simpler and more patient-friendly diagnostic approach.",[26,27],"Arginine Vasopressin Deficiency","Primary Polydipsia",[29,30,31,32],"Copeptin Measurement","Diagnosis of Polyuria-polydipsia syndrome","Mannitol","Hypertonic Saline Infusion","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"2026-06-16",{"date":41,"type":20},"2030-06",{"name":43,"class":44},"University Hospital, Basel, Switzerland","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":17,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100562577","arginin-stimulated-copeptin-in-polyuria-polydipsia-syndrome-in-children-100562577","NCT06604975","Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children","COPEPCHILD","Inclusion Criteria:\n\n* Children aged 2 to 18 years with polyuro-polydipsia syndrome (defined as hypotonic diuresis \\> 50 mL\u002Fkg\u002Fday in pediatric age or 30 mL\u002Fkg\u002Fday in late puberty (Tanner 5)) presenting for differential diagnosis between PP and DIC\n* Basal copeptin of less than 30 pmol\u002Fl\n* Agreeing to participate in the study\n* Whose two parents' consent to have their child participate in the study.\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Unbalanced dysthyroidism\n* Corticotropic deficiency\n* Ionic disorders (dysnatremia \\< 135 or \\> 145 mmol\u002Fl, dyskalemia \\< 3 or \\> 5 mmol\u002Fl, corrected dyscalcemia \\< 2.2 or \\> 2.6 mmol\u002FL)\n* Moderate to severe clinical dehydration (recent weight loss \\> 5% of body weight, clinical or biological signs of dehydration) requiring immediate therapeutic management\n* Renal failure with GFR \\< 60 mL\u002Fmin\u002F1.73 m2\n* Uropathy\n* Tumor syndrome (except hypothalamo-pituitary tumor)\n* Intracranial hypertension\n* ROHHAD syndrome\n* Fever or biological inflammatory syndrome with CRP \\> 5 mg\u002FL\n* Hepatic insufficiency\n* Contraindication to MRI\n* Contraindication to progressive water intake restrictions\n* History of contraindication to arginine\n* Positive test for Pregnancy\n* Lack of authorization by both parents or legal representatives","2 Years",{"count":55,"type":20},155,[23],"The exploration of polyuro-polydipsia syndrome (PPS) with hypotonic polyuria should distinguished, primary polydipsia (PP) due to excessive water intake, central diabetes insipidus (CDI) related to insufficient secretion of antidiuretic hormone (AVP), and nephrogenic diabetes insipidus (NDI) related to AVP insensitivity. The determination of plasma AVP is not relevant (unstable concentration, short in vitro half-life, long technical time and large blood sample). The differential diagnosis is currently based on a water deprivation test (WDT), an indirect reflection of AVP action, requiring more than 6 hours of hospitalization with risk of dehydration and low accuracy. Copeptin represents a new biomarker, direct mirror of AVP release with remarkable characteristics (stable, rapid determination, small blood volume). Copeptin has become a diagnostic tool in adult PPS and eliminated WDT in the diagnostic process. In children, basal copeptin values help for NDI and to exclude CDI (basal copeptin threshold \\> 30 and \\> 3.53 pmol\u002Fl (Se 100%, Sp 87.4%), respectively). Below 3.53 pmol\u002Fl, basal copeptin performance was inadequate to discriminate PP and CDI, highlighting the relevance of the stimulated copeptin study to improve this strategy. The arginine stimulation test is widely used as a simple, short duration (2 hours) and well tolerated tool to diagnose growth hormone deficiency in pediatrics. The performance of this test for copeptin stimulation was studied in adults with PPS with a high diagnostic accuracy.\n\nThe aim of the study is identify the best discriminant threshold of the arginine stimulation test in the uncertain diagnosis (basal copeptin \\\u003C30 pmol\u002Fl) in the polyuro-polydipsic syndrome in children.\n\nThen evaluate the discriminative capacities of the arginine stimulation test between the primary polydipsia and central insipid diabetes in the polyuro-polydipsic syndrome in children. And finally evaluate the cost-effectiveness of a new decisional algorithm for the differential diagnosis of PPS in children and evaluate the impact of infusion volume on copeptin secretion using the protidemia copeptin ratio.",[27,59,60],"Central Diabetes Insipidus","Nephrogenic Diabetes Insipidus","NOT_YET_RECRUITING","2025-02-12",{"date":64,"type":37},"2025-02-13",{"date":66,"type":20},"2025-03",{"date":68,"type":20},"2028-07",{"name":70,"class":44},"Assistance Publique Hopitaux De Marseille",14]